Home > Insider Trading > Filing (0001209191-21-025503)

Filing Details

Accession Number:: 0001209191-21-025503
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-04-05 19:50:57
Reporting Period:: 2021-04-01

Accepted Time:: 2021-04-05 19:50:57
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1661460	Poseida Therapeutics Inc.	PSTX	Biological Products, (No Disgnostic Substances) (2836)	472846548

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1765987	Eric Ostertag	C/O Poseida Therapeutics, Inc. 9390 Towne Centre Drive, Ste 200 San Diego CA 92121	Chief Executive Officer	Yes	Yes	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-04-01	29,834	$9.55	3,882,383	No	4	S	Indirect	See footnote
Common Stock	Disposition	2021-04-05	28,549	$9.63	3,853,834	No	4	S	Indirect	See footnote
Common Stock	Disposition	2021-04-05	1,617	$10.32	3,852,217	No	4	S	Indirect	See footnote
Common Stock	Disposition	2021-04-01	27,347	$9.55	3,560,277	No	4	S	Indirect	See footnote
Common Stock	Disposition	2021-04-05	26,170	$9.63	3,534,107	No	4	S	Indirect	See footnote
Common Stock	Disposition	2021-04-05	1,483	$10.32	3,532,624	No	4	S	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	542,985	Direct
Common Stock	629,194	Indirect	See footnote
Common Stock	961,445	Indirect	See footnote
Common Stock	200,696	Indirect	See footnote

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2020.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.21 to $10.00 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares are held in the name of the Eric Ostertag Living Trust dated March 30, 2016, of which the reporting person is the sole trustee.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.28 to $10.27 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within therange set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.28 to $10.38 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within therange set forth in this footnote.
The shares are held in the name of Titan, LLC, which is owned by the Ostertag Descendents' Trust, of which the reporting person's minor daughter is the sole beneficiary. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
The shares are held in the name of Twin Prime Investments, an entity wholly owned by the reporting person.
The shares are held in the name of Transposagen Biopharmaceuticals, Inc., of which Dr. Ostertag is a majority stockholder.